Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings plc

Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. 

See our community guidelines: http://bit.ly/2kFA8hr

Oxford Finance LLC

General Atlantic

Rock Springs Capital

RTW Investments

WuXi AppTec

Bill & Melinda Gates Foundation

Terra Magnum Capital Partners (""""TMCP"""")""

CCB International

JDRF T1D Fund

BlackRock

Immunocore

Unhealthy cells have evolved mechanisms for evading T cells, making diseases like cancer harder to treat. 

ImmTAC molecules contain a T cell receptor that has been engineered to better recognise its target and seek out evading cells. #IMCRSharing #innovation

It is by living our values daily that we are able to develop transformative treatments and to innovate for patients. #WeAreIMCR #innovation #ResearchAndDevelopment

Looking to advance your career in Regulatory Affairs? Apply for our Regulatory Submissions Manager position and grow within a highly innovative, agile, and entrepreneurial environment. https://lnkd.in/eu7WxW_v #WeAreIMCR #hiring #biotechjobs

Gynecologic cancers account for nearly 40% of cancer cases & 1/3 of cancer deaths in women. We must continue the search for new treatments & prevention measures to save the lives of women across the globe. #CervicalCancerPreventionWeek #CervicalCancerAwarenessMonth #WeAreIMCR

Come and apply the principles of effective clinical project practices at a pioneering biotech. #WeAreIMCR #biotechjobs #hiring
https://lnkd.in/eTSVJJcC

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-71.63M -	-103.93M 45.09%	-74.09M 28.71%	-131.52M 77.51%	-41.22M 68.66%	-55.29M 34.11%
depreciation and amortization	6.71M -	9.21M 37.36%	8.98M 2.57%	7.01M 21.88%	6.13M 12.56%	4.09M 33.29%
deferred income tax	-16.55M -	-22.26M 34.51%	-13.27M 40.39%	-9.40M 29.11%	-2.92M 68.94%	13.83M 573.37%
stock based compensation	666K -	3.06M 358.86%	8.16M 167.08%	35.86M 339.37%	27.05M 24.56%	32.47M 20.02%
change in working capital	67.58M -	-10.09M 114.93%	-28.80M 185.40%	-16.81M 41.65%	-12.88M 23.33%	5.78M 144.87%
accounts receivables		1.83M -	-532K 129.10%	-5.15M 867.48%	-32.09M 523.47%	-17.87M 44.31%
inventory				-1.47M -	-4.91M 233.31%	29.04M 691.11%
accounts payables				1.47M -	4.91M 233.31%	2.63M 46.57%
other working capital	67.58M -	-11.92M 117.64%	-28.27M 137.17%	-11.66M 58.76%	19.20M 264.72%	-8.01M 141.72%
other non cash items	-3.40M -	22.64M 766.55%	38.45M 69.87%	-14.89M 138.72%	-7.42M 50.13%	2.06M 127.73%
net cash provided by operating activities	-16.63M -	-101.38M 509.74%	-60.57M 40.25%	-129.75M 114.20%	-31.27M 75.90%	2.94M 109.40%
investments in property plant and equipment	-3.54M -	-4.28M 20.89%	-3.07M 28.11%	-1.01M 67.21%	-2.20M 117.96%	-5.42M 146.93%
acquisitions net
purchases of investments
sales maturities of investments	27.45M -
other investing activites	34.10M -	139K 99.59%	3.54M 2,447.48%	513K 85.51%	2.43M 373.68%
net cash used for investing activites	58.01M -	-4.14M 107.13%	467K 111.29%	-495K 206.00%	233K 147.07%	-5.42M 2,428.33%
debt repayment		-4.04M -	-4.43M 9.66%	-3.16M 28.63%	-46.72M 1,378.85%
common stock issued		59.87M -	83.22M 38.99%	226.53M 172.21%	116.81M 48.43%
common stock repurchased
dividends paid
other financing activites	101K -	-711K 803.96%	37.15M 5,324.89%	52.88M 42.35%	68.13M 28.83%	34.35M 49.59%
net cash used provided by financing activities	101K -	55.13M 54,481.19%	115.94M 110.32%	276.25M 138.27%	138.23M 49.96%	34.35M 75.15%
effect of forex changes on cash	13K -	-33K 353.85%	-84K 154.55%	22K 126.19%	7.12M 32,272.73%	8.29M 16.44%
net change in cash	41.50M -	-50.42M 221.49%	55.75M 210.57%	146.03M 161.94%	114.31M 21.72%	40.15M 64.87%
cash at beginning of period	82.88M -	124.39M 50.07%	73.97M 40.53%	175.12M 136.75%	287.30M 64.06%	402.47M 40.09%
cash at end of period	124.39M -	73.97M 40.53%	129.72M 75.37%	321.15M 147.58%	401.61M 25.05%	442.63M 10.21%
operating cash flow	-16.63M -	-101.38M 509.74%	-60.57M 40.25%	-129.75M 114.20%	-31.27M 75.90%	2.94M 109.40%
capital expenditure	-3.54M -	-4.28M 20.89%	-3.07M 28.11%	-1.01M 67.21%	-2.20M 117.96%	-5.42M 146.93%
free cash flow	-20.16M -	-105.65M 423.99%	-63.65M 39.76%	-130.76M 105.44%	-33.47M 74.41%	-2.48M 92.57%

NASDAQ:IMCR

Immunocore Holdings plc

Last Close

54.25

17/05 20:00

Market Cap

3.46B

Beta: 0.55

Volume Today

786.95K

Avg: 266.28K

PE Ratio

−53.27

PFCF: 257.21